摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-amino-6-fluoro-N-[5-fluoro-4-(1-methyl-1H-imidazol-5-yl)pyridin-3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide | 674783-97-2

中文名称
——
中文别名
——
英文名称
2-amino-6-fluoro-N-[5-fluoro-4-(1-methyl-1H-imidazol-5-yl)pyridin-3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
英文别名
Tuvusertib;2-amino-6-fluoro-N-[5-fluoro-4-(3-methylimidazol-4-yl)pyridin-3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
2-amino-6-fluoro-N-[5-fluoro-4-(1-methyl-1H-imidazol-5-yl)pyridin-3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide化学式
CAS
674783-97-2
化学式
C16H12F2N8O
mdl
——
分子量
370.321
InChiKey
RBQPCTBFIPVIJN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 溶解度:
    溶于丙酮

计算性质

  • 辛醇/水分配系数(LogP):
    0.2
  • 重原子数:
    27
  • 可旋转键数:
    3
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.06
  • 拓扑面积:
    116
  • 氢给体数:
    2
  • 氢受体数:
    8

安全信息

  • 危险等级:
    5.1
  • 危险品标志:
    O,Xi
  • 安全说明:
    S26
  • 危险类别码:
    R8,R36/37/38
  • WGK Germany:
    3
  • 海关编码:
    29339900

SDS

SDS:c6571bf8a21d371cd647c78bad00747c
查看

制备方法与用途

应用领域中提到,**10-甲基-9-均三甲苯基吖啶高氯酸盐**是一种杂环有机化合物。文献报道指出,该物质可用于制备安息香双醚。

其制备方法为:通过一步反应将2-溴-1,3,5-三甲基苯N-甲基吖啶酮结合,即可得到所需的目标产物。

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE FOR THE TREATMENT OF CANCER DISEASES
    申请人:Vertex Pharmaceuticals Inc.
    公开号:EP3418281A1
    公开(公告)日:2018-12-26
    The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: or a pharmaceutically acceptable salt, wherein the variables are as devined herein. Moreover, The compounds of this invention have formula I-A: or a pharmaceutically acceptable salt, wherein the variables are as defined herein.
    本发明涉及可用作 ATR 蛋白激酶抑制剂的化合物。本发明还涉及包含本发明化合物的药学上可接受的组合物;使用本发明化合物治疗各种疾病、失调和病症的方法;制备本发明化合物的工艺;制备本发明化合物的中间体;以及在体外应用中使用本发明化合物的方法,例如研究生物和病理现象中的激酶;研究由这些激酶介导的细胞内信号转导途径;以及比较评估新的激酶抑制剂。 本发明的化合物具有式 I: 或药学上可接受的盐,其中变量如本文所设计。 此外,本发明的化合物具有式 I-A: 或药学上可接受的盐,其中变量如本文所定义。
  • COMBINATION OF A DNA DAMAGE RESPONSE CELL CYCLE CHECKPOINT INHIBITORS AND BELINOSTAT FOR TREATING CANCER
    申请人:ONXEO
    公开号:EP3461480A1
    公开(公告)日:2019-04-03
    The present invention relates to the combination of a DNA damage response (DDR) cell cycle checkpoint inhibitor selected from the group consisting of an ATR inhibitor (ATRi) and a CHK1 inhibitor (CHKli) and belinostat for treating cancer.
    本发明涉及选自 ATR 抑制剂(ATRi)和 CHK1 抑制剂(CHKli)组成的组的 DNA 损伤应答(DDR)细胞周期检查点抑制剂与贝利诺司他的组合,用于治疗癌症。
  • 2-AMINO-N-(PIPERIDIN-1-YL-PYRIDIN-3-YL) PYRAZOLO[1,5ALPHA]PYRIMIDINE-3-CARBOXAMID AS INHIBITOR OF ATR KINASE
    申请人:Vertex Pharmaceuticals Incorporated
    公开号:EP3486245A1
    公开(公告)日:2019-05-22
    The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: or a pharmaceutically acceptable salt, wherein the variables are as devined herein. Moreover, The compounds of this invention have formula I-A: or a pharmaceutically acceptable salt, wherein the variables are as defined herein.
    本发明涉及可用作 ATR 蛋白激酶抑制剂的化合物。本发明还涉及包含本发明化合物的药学上可接受的组合物;使用本发明化合物治疗各种疾病、失调和病症的方法;制备本发明化合物的工艺;制备本发明化合物的中间体;以及在体外应用中使用本发明化合物的方法,例如研究生物和病理现象中的激酶;研究由这些激酶介导的细胞内信号转导途径;以及比较评估新的激酶抑制剂。 本发明的化合物具有式 I: 或药学上可接受的盐,其中变量如本文所设计。 此外,本发明的化合物具有式 I-A: 或药学上可接受的盐,其中变量如本文所定义。
  • Compounds useful as inhibitors of ATR kinase
    申请人:Vertex Pharmaceuticals Incorporated
    公开号:US10093676B2
    公开(公告)日:2018-10-09
    The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and solid forms of the compounds of this invention. The compounds of this invention have formula I-1 or I-A: wherein the variables are as defined herein.
    本发明涉及可用作 ATR 蛋白激酶抑制剂的化合物。本发明涉及包含本发明化合物的药学上可接受的组合物;使用本发明化合物治疗各种疾病、失调和病症的方法;制备本发明化合物的工艺;制备本发明化合物的中间体;以及本发明化合物的固体形式。 本发明的化合物具有式 I-1 或 I-A: 其中变量如本文所定义。
  • Method for treating cancer using a combination of Chk1 and ATR inhibitors
    申请人:Vertex Pharmaceuticals Incorporated
    公开号:US11179394B2
    公开(公告)日:2021-11-23
    The present invention relates to methods of treating cancer in a patient by administering a compound useful as an inhibitor of ATR protein kinase in combination with a compound useful as an inhibitor of Chk1 protein kinase. The aforementioned combination displays a surprising synergistic effect in treating cancer despite the targeted protein kinases being within the same biological pathway. Moreover, the present invention also relates to methods of treating cancer by administering a compound useful as an inhibitor of ATR protein kinase; administering a compound useful as an inhibitor of Chk1 protein kinase; as well as administering a DNA damaging agent to a patient. The compounds utilized in this invention are represented by formula I and formula II: wherein the variables are as defined herein.
    本发明涉及通过施用一种可作为 ATR 蛋白激酶抑制剂的化合物和一种可作为 Chk1 蛋白激酶抑制剂的化合物来治疗患者癌症的方法。尽管靶向蛋白激酶属于同一生物通路,但上述组合在治疗癌症方面显示出惊人的协同效应。此外,本发明还涉及治疗癌症的方法,即给患者施用一种可作为 ATR 蛋白激酶抑制剂的化合物;给患者施用一种可作为 Chk1 蛋白激酶抑制剂的化合物;以及给患者施用一种 DNA 损伤剂。 本发明中使用的化合物由式I和式II表示: 其中变量如本文所定义。
查看更多

同类化合物

阿拉格列汀 间型霉素环-3',5'-单磷酸酯 西地那非杂质 西地那非-嘧啶酮杂质 苯甲腈,4-(5-甲基-1,3-噁噻戊环-2-基)-(9CI) 苯,[(1-甲基环戊基)硫代]- 苄基-(6-氯-1-甲基-1H-吡唑并[3,4-d]嘧啶-4-基)-胺 羟基氯地那非 磷酸二氢2-甲氧基-5-[(Z)-2-(3,4,5-三甲氧苯基)乙烯基]苯酯 盐(1:?)1,3,5-萘三磺酸,7-[2-[4-[[5-氯-6-甲基-2-(甲磺酰)-4-嘧啶基]氨基]苯基]二氮烯基]-,钠 甲基-(6-甲基磺酰基-1(2)H-吡唑并[3,4-d]嘧啶-4-基)-胺 甲基(1R,2S,4S)-2,5,7-三羟基-6,11-二羰基-2-(2-羰基丙基)-4-{[2,3,6-三脱氧-4-O-(2,6-二脱氧-α-L-来苏-六吡喃糖基)-3-(二甲氨基)-α-L-来苏-六吡喃糖基]氧代}-1,2,3,4,6,11-六氢四省-1-羧酸酯 环己基-(1-甲基-1H-吡唑并[3,4-d]嘧啶-4-基)-胺 氯化[4-[(4-氯苯基)氰基甲基]-5-氯-m-苯甲基]铵 氮杂环庚-1-基-[7-氯-4-噻吩-2-基-2-(三氟甲基)-1,5,9-三氮杂双环[4.3.0]壬-2,4,6,8-四烯-8-基]甲酮 昔多芬杂质 异丙基 4-(1-甲基-7-氧代-3-丙基-6,7-二氢-1H-吡唑并[4,3-d]嘧啶-5-基)噻吩-2-基磺酰基氨基甲酸酯 噁庚并[3,4-c]吡啶-3,9-二酮,5-乙基-1,4,5,8-四氢-5-羟基-,(5R)- 吡啶-2-基-[7-吡啶-4-基-吡唑[1,5-a]嘧啶-3-基]甲酮 吡唑并[2,3-a]嘧啶 吡唑并[1,5-a]嘧啶-7-胺 吡唑并[1,5-a]嘧啶-7(1h)-酮 吡唑并[1,5-a]嘧啶-6-醇 吡唑并[1,5-a]嘧啶-6-羧酸乙酯 吡唑并[1,5-a]嘧啶-6-羧酸 吡唑并[1,5-a]嘧啶-5-羧酸,3-氰基-4,7-二氢-7-羰基-,甲基酯 吡唑并[1,5-a]嘧啶-5-羧酸 吡唑并[1,5-a]嘧啶-3-胺盐酸盐(1:1) 吡唑并[1,5-a]嘧啶-3-胺;三氟乙酸 吡唑并[1,5-a]嘧啶-3-羰酰氯 吡唑并[1,5-a]嘧啶-3-羧酸乙酯 吡唑并[1,5-a]嘧啶-3-羧酸 吡唑并[1,5-a]嘧啶-3-磺酰胺 吡唑并[1,5-a]嘧啶-3-甲酰胺 吡唑并[1,5-a]嘧啶-3-甲腈 吡唑并[1,5-a]嘧啶-2-羧酸乙酯 吡唑并[1,5-a]嘧啶-2-羧酸 吡唑并[1,5-a]嘧啶,2-甲基-6-(1-甲基乙基)- 吡唑并[1,5-a]嘧啶,2-溴-5,7-二甲基- 吡唑并[1,5-A]嘧啶-7-羧酸 吡唑并[1,5-A]嘧啶-5-胺 吡唑并[1,5-A]嘧啶-5(4H)-酮 吡唑并[1,5-A]嘧啶-3-甲醛 吡唑[1,5-A]嘧啶-5-羧酸甲酯 吡唑[1,5-A]嘧啶-5,7(4H,6H)-二酮 双氯地那非 卡巴地那非 别嘌醇 别嘌呤醇D2 依鲁替尼杂质37